Valuation: Armata Pharmaceuticals, Inc.

Market Cap 135M 119M 112M 102M 191M 12.96B 192M 1.34B 520M 6.61B 508M 497M 21.43B P/E 2026 *
-1.95x
P/E 2027 * -2.52x
Enterprise Value 135M 119M 112M 102M 191M 12.96B 192M 1.34B 520M 6.61B 508M 497M 21.43B EV / Sales 2026 *
31.8x
EV / Sales 2027 * 49.2x
Free-Float
32.36%
Yield 2026 *
-
Yield 2027 * -
1 day-13.33%
1 week-10.57%
Current month-33.94%
1 month-28.63%
3 months-48.07%
6 months-55.01%
Current year-42.04%
1 week 3.6
Extreme 3.6
4.56
1 month 3.6
Extreme 3.6
6.64
Current year 3.48
Extreme 3.48
14.98
1 year 2.94
Extreme 2.94
16.34
3 years 0.9
Extreme 0.8981
16.34
5 years 0.83
Extreme 0.8311
16.34
10 years 0.83
Extreme 0.8311
16.34
Manager TitleAgeSince
Chief Executive Officer 70 2023-07-10
Director of Finance/CFO 42 2024-08-15
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 62 2019-05-08
Director/Board Member 66 2020-02-11
Director/Board Member 51 2020-02-11
Date Insider Type Main position Quantity % Market Cap. Importance
7/10/26 Tax

Chief Executive Officer

-14,041 0.0382%
4/24/26 Free

Director

51,280 0.1400%
3/14/26 Tax

Public Communications Manager

1,030 0.0028%
Change 5-day change 1-year change 3-year change Capi.($)
-13.33%-10.57%+19.34%+35.82% 135M
+0.06%+6.49%+60.29%+111.13% 74.18B
-0.43%-4.17%+33.73%+74.31% 59.55B
-2.05%-3.46%-18.60%+352.20% 25.84B
-2.39%+2.74%+0.19%-5.91% 24.73B
-1.11%+1.34%+21.77%-9.80% 20.87B
+1.29%-2.49%+152.11%+333.06% 15.32B
-2.44%-0.09%+42.50%+164.11% 14.06B
-3.91%-4.91%-14.10%+779.68% 13.12B
-1.12%-3.04%+15.72%+234.56% 11.85B
Average -2.55%-1.42%+31.30%+206.92% 25.97B
Weighted average by Cap. -0.93%+0.70%+36.17%+161.15%

Financials

2026 *2027 *
Net sales 4.25M 3.73M 3.51M 3.21M 5.99M 407M 6.04M 42.12M 16.33M 208M 15.96M 15.61M 673M 2.75M 2.41M 2.27M 2.07M 3.88M 263M 3.9M 27.25M 10.56M 134M 10.33M 10.1M 435M
Net income -76.6M -67.23M -63.2M -57.78M -108M -7.34B -109M -759M -294M -3.74B -288M -281M -12.13B -72M -63.19M -59.4M -54.31M -101M -6.9B -102M -714M -277M -3.52B -270M -264M -11.4B
Net Debt - -
Logo Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.
Employees
61
Date Price Change Volume
26-09-23 US$3.640 -13.33% 287,063
26-09-22 US$4.200 -1.41% 128,357
26-09-21 US$4.260 +1.91% 82,899
26-09-18 US$4.180 +1.95% 160,607
26-09-17 US$4.100 +0.74% 253,540
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.640USD
Average target price
17.50USD
Spread / Average Target
+380.77%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARMP Stock